Loading clinical trials...
Loading clinical trials...
A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
Conditions
Interventions
semaglutide
placebo
Locations
1
United Kingdom
Novo Nordisk Investigational Site
Leeds, United Kingdom
Start Date
March 6, 2014
Primary Completion Date
January 7, 2015
Completion Date
January 7, 2015
Last Updated
December 2, 2017
NCT07472881
NCT01143454
NCT07051005
NCT00001987
NCT07296484
NCT07010757
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions